ESMO Breast 2020 and Immuno Oncology View overview page

7:15
Characterizing the immune microenvironment before and following anti-HER2 neoadjuvant therapy
Gaia Griguolo • 12 May 2020
6:19
The future of breast cancer treatment
Gaia Griguolo • 21 May 2020
2:42
LILAC: comparing cardiac safety of ABP 980 with trastuzumab
Hans-Christian Kolberg • 13 May 2020
3:26
Chemo-immunotherapy for TNBC
Evandro de Azambuja • 20 May 2020
2:06
PHranceSCa: evaluating patient satisfaction with subcutaneous pertuzumab and trastuzumab treatment
Evandro de Azambuja • 12 May 2020
1:01
Chemo-immunotherapy for TNBC
Serafin Morales • 12 May 2020
6:46
SAFIR02-IMMUNO: PDL1 copy number changes predicts checkpoint blockade inhibitor efficacy in mBC
Thomas Bachelot • 22 May 2020
7:09
Personalizing immunotherapy beyond PDL1 expression
Marleen Kok • 14 May 2020
10:07
Importance of biomarkers when evaluating heterogeneity in HER2+ metastatic BC
Maria Vittoria Dieci • 26 May 2020
1:11
Current standards for HER2+ early stage breast cancer
Sara Tolaney
6:15
Beyond HER2: dissecting tumor heterogeneity
Aleix Prat • 14 May 2020
2:01
HER2CLIMB: tucatinib in combination w/ capecitabine & trastuzumab
Giuseppe Curigliano • 14 May 2020
2:43
CLEOPATRA & EMILIA: HER2+ mBC state-of-the-art
Sandra Swain • 7 May 2020
1:24
Cabo alone or with trast for BC with brain mets?
Sara Tolaney • 14 May 2020
1:56
NSABP B-41: genes and signatures associated with pCR
Sandra Swain • 7 May 2020
2:49
HER2-E pCR with anti-HER2-based neoadjuvant therapies
Aleix Prat • 18 May 2020
The content of VJOncology is intended for healthcare professionals